Hero

Press Releases

Press Releases

Royalty Pharma Acquires Royalty Interest in Cabozantinib from GSK

NEW YORK, NY, April 1, 2021 – Royalty Pharma plc (Nasdaq: RPRX) today announced that it has acquired a royalty interest in the cabozantinib products Cabometyx and Cometriq from GlaxoSmithKline (GSK) for an upfront payment of $342 million and up to $50 million in additional payments contingent on

Royalty Pharma Appoints Henry A. Fernandez as Lead Independent Director

NEW YORK, NY, March 30, 2021 – The Board of Directors of Royalty Pharma plc (Nasdaq: RPRX) today announced that the independent directors of the Board have unanimously appointed Henry A. Fernandez as Lead Independent Director. Mr. Fernandez is Chairman and Chief Executive Officer of MSCI Inc.

Royalty Pharma Reports Q4 2020 and Full-Year Results

NEW YORK , Feb. 17, 2021 - Double-digit growth in Net cash provided by operating activities (GAAP) and Adjusted Cash Flow $2.4 billion of acquisitions announced in 2020; maintained leading share of biopharma royalty funding market Increasing outlook for 2020-2025 Adjusted Cash Receipts CAGR to 7%-10%

Royalty Pharma to Announce Fourth-Quarter 2020 Financial Results on February 17, 2021

NEW YORK, NY, January 22, 2021 – Royalty Pharma plc (Nasdaq: RPRX) today announced that it will report its fourth quarter 2020 financial results on Wednesday, February 17, 2021 before the U.S. financial markets open. The company will host a conference call and simultaneous webcast at 8:00 a.m.

Royalty Pharma Acquires Royalty Interest in Seltorexant from Minerva Neurosciences

NEW YORK, NY and WALTHAM, MA, January 19, 2021 – Royalty Pharma plc (Nasdaq: RPRX) and Minerva Neurosciences, Inc. (Nasdaq: NERV) today announced that Royalty Pharma will acquire Minerva’s royalty interest in seltorexant for an upfront payment of $60 million and up to $95 million in additional

Royalty Pharma Announces 13% Dividend Increase

NEW YORK, NY, January 8, 2021 - Royalty Pharma plc (Nasdaq: RPRX) today announced that its board of directors has declared a dividend for the first quarter of 2021 of $0.17 per class A share, reflecting a 13% increase in the company’s quarterly dividend over the previous quarter’s dividend.

Royalty Pharma to Present at the J.P. Morgan Healthcare Conference on January 12

NEW YORK, NY – JANUARY 7, 2021 - Royalty Pharma plc (Nasdaq: RPRX) today announced that management will present at the 39 th Annual J.P. Morgan Healthcare Conference on Tuesday, January 12, 2021 at 10:50 a.m. EST. Investors, analysts, members of the media and the general public are invited to

Royalty Pharma Announces Expansion of Leadership Team

NEW YORK , Dec. 21, 2020 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced an expansion of its leadership team: Jim Reddoch , PhD will assume increased responsibilities with a new role of Chief Scientific Officer, which is in addition to his position as Co-Head of Research &

Royalty Pharma Acquires Royalty Interest In Orladeyo and BCX9930 from Biocryst Pharmaceuticals

NEW YORK, NY and RESEARCH TRIANGLE PARK, N.C, December 7, 2020 – Royalty Pharma (Nasdaq: RPRX), BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) and Athyrium Capital Management, LP today announced transactions totaling $325 million in funding for BioCryst, with $250 million available at closing, to

Royalty Pharma Reports Third Quarter 2020 Results

Double-digit growth in Net cash provided by operating activities (GAAP) and Adjusted Cash Receipts Increased 2020 guidance: Adjusted Cash Receipts expected to be $1,780 to $1,800 million $2.3 billion of new acquisitions announced in 2020, including $1.1 billion in the third quarter

Displaying 61 - 70 of 121